Claims
- 1. A composition comprising an isolated, adult Taenia solium excretory/secretory polypeptide.
- 2. The composition of claim 1 wherein the polypeptide has a molecular weight selected from the group of approximately 33 kDa, 38 kDa, and 42 kDa, as determined by SDS-PAGE analysis.
- 3. The composition of claim 1 wherein the polypeptide has a molecular weight selected from the group of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, as determined by SDS-PAGE analysis.
- 4. The composition of claim 1 wherein the polypeptide is a mixture of two or more isolated, adult Taenia solium excretory/secretory polypeptides having a molecular weight selected from the group of approximately 33 kDa, 38 kDa, and 42 kDa, as determined by SDS-PAGE analysis.
- 5. The composition of claim 1 wherein the polypeptide is a mixture of two or more isolated, adult Taenia solium excretory/secretory polypeptides having a molecular weight selected from the group of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, as determined by SDS-PAGE analysis.
- 6. The composition of claim 1 wherein the polypeptide is a mixture of three isolated, adult Taenia solium excretory/secretory polypeptides having molecular weights of approximately 33 kDa, 38 kDa, and 42 kDa, respectively, as determined by SDS-PAGE analysis.
- 7. The composition of claim 1 wherein the polypeptide is a mixture of three isolated, adult Taenia solium excretory/secretory polypeptides having molecular weights of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, respectively, as determined by SDS-PAGE analysis.
- 8. A method for detecting T. solium in a biological sample comprising combining the sample with a composition comprising an isolated, adult Taenia solium excretory/secretory polypeptide and detecting the binding of the polypeptide to an anti-polypeptide antibody in the sample.
- 9. The method of claim 8 wherein the polypeptide has a molecular weight selected from the group of approximately 33 kDa, 38 kDa, and 42 kDa, as determined by SDS-PAGE analysis.
- 10. The method of claim 8 wherein the polypeptide has a molecular weight selected from the group of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, as determined by SDS-PAGE analysis.
- 11. The method of claim 8 wherein the polypeptide is a mixture of two or more isolated, adult Taenia solium excretory/secretory polypeptides having a molecular weight selected from the group of approximately 33 kDa, 38 kDa, and 42 kDa, as determined by SDS-PAGE analysis.
- 12. The method of claim 8 wherein the polypeptide is a mixture of two or more isolated, adult Taenia solium excretory/secretory polypeptides having a molecular weight selected from the group of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, as determined by SDS-PAGE analysis.
- 13. The method of claim 8 wherein the polypeptide is a mixture of three isolated, adult Taenia solium excretory/secretory polypeptides having molecular weights of approximately 33 kDa, 38 kDa, and 42 kDa, respectively, as determined by SDS-PAGE analysis.
- 14. The method of claim 8 wherein the polypeptide is a mixture of three isolated, adult Taenia solium excretory/secretory polypeptides having molecular weights of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, respectively, as determined by SDS-PAGE analysis.
- 15. The method of claim 8 wherein the binding is detected by immunoassay.
- 16. The method of claim 15 wherein the immunoassay is an immunoblot assay.
- 17. The method of claim 8 wherein the biological sample is a biological fluid.
- 18. The method of claim 8 wherein the biological sample is a biological fluid selected from the group consisting of blood serum, blood plasma and saliva.
- 19. A method for diagnosing taeniasis in a human comprising contacting a biological sample of the human with an adult Taenia solium excretory/secretory polypeptide and detecting the binding of antibody present in the biological sample to the polypeptide, wherein the detection of binding indicates taeniasis.
- 20. The method of claim 19 wherein the polypeptide has a molecular weight selected from the group consisting of approximately 33 kDa, 38 kDa, and 42 kDa, as determined by SDS-PAGE analysis.
Parent Case Info
[0001] This patent application claims priority to U.S. Provisional Patent Application No. 60/111,334 filed Dec. 7, 1998.
Government Interests
[0002] This invention was made by the Centers for Disease Control, an agency of the United States Government.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60111334 |
Dec 1998 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09454753 |
Dec 1999 |
US |
Child |
10072722 |
Feb 2002 |
US |